tepotinib
Selected indexed studies
- Tepotinib. (, 2006) [PMID:34554673]
- Tepotinib. (, 2012) [PMID:37782745]
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. (N Engl J Med, 2020) [PMID:32469185]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tepotinib. (2006) pubmed
- Tepotinib. (2012) pubmed
- Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. (2020) pubmed
- Tepotinib: First Approval. (2020) pubmed
- Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial. (2023) pubmed
- Tepotinib in patients with MET exon 14 skipping non-small cell lung cancer. (2025) pubmed
- Tepotinib hydrochloride for the treatment of non-small cell lung cancer. (2021) pubmed
- Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. (2024) pubmed
- PMID:40472119 (2022) pubmed
- The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations. (2023) pubmed